Eiken Chemical announced that the US Food and Drug Administration (FDA) had approved Eiken's proprietary automated immunochemistry analyzer and reagent for fecal occult blood tests.
From mid-November, Eiken will distribute the OC-Auto MICRO 80 analyzer and the Clearview ULTRA FOB Test reagent in the US through its sales partners Nagase and POLYMEDCO of New York.
The US market for fecal occult blood testing products is estimated at 10 billion yen ($94 mil). As part of its global strategies, Eiken is aiming for a larger market share in the US.